Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-22

Study Completion Date

2029-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized controlled, prospective clinical study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

NCT04156698

Hypopharyngeal Carcinoma Immunotherapy Chemotherapy

ACTIVE_NOT_RECRUITING PHASE2

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

NCT04995120

Laryngeal Cancer Hypopharynx Cancer Laryngeal Neoplasms

RECRUITING PHASE2

A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

NCT07062484

Lung Metastatic Nasopharyngeal Carcinoma

NOT_YET_RECRUITING NA

Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma

NCT00817258

Nasopharyngeal Carcinoma

UNKNOWN PHASE2

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

NCT06151743

Locally Advanced Hypopharyngeal Carcinoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The early symptoms of hypopharyngeal cancer are often inconspicuous, with approximately 70% of patients clinically diagnosed at an advanced stage. With the emergence of immunotherapy, immune therapies such as PD-1 inhibitors combined with induction chemotherapy have been widely explored in various tumor types. Currently, there is a lack of large-scale real-world studies on the efficacy and safety of treatment options for patients with locally advanced hypopharyngeal cancer who respond well to neoadjuvant therapy. This study aims to employ neoadjuvant chemotherapy combined with immunotherapy for locally advanced hypopharyngeal cancer and explore the effectiveness and safety of different subsequent treatment options for patients assessed as achieving a major partial response (PR ≥50%).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypopharyngeal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

neoadjuvant therapy followed by surgery and (C)RT group

Patients initially receive immunotherapy with Finolizumab and chemotherapy with albumin-bound paclitaxel and cisplatin. Patients with response of complete reaction (CR)/partial reaction (PR)≥50% after neoadjuvant chemotherapy then receive surgery, followed by postoperative radiotherapy or chemoradiotherapy.

Group Type EXPERIMENTAL

Finolizumab

Intervention Type DRUG

200mg every 3 weeks (q3w) for 2 cycles.

Albumin-Bound Paclitaxel /nab-Paclitaxel

Intervention Type DRUG

260mg/m², day 1, every 3 weeks (q3w) for 2 cycles.

Cisplatin

Intervention Type DRUG

25mg/m², days 1-3, every 3 weeks (q3w) for 2 cycles.

Surgery with postoperative radiotherapy or chemoradiotherapy.

Intervention Type PROCEDURE

surgery with postoperative radiotherapy or chemoradiotherapy.

neoadjuvant therapy followed by CCRT group

Patients initially receive immunotherapy with Finolizumab and chemotherapy with albumin-bound paclitaxel and cisplatin. Patients with response of complete reaction (CR)/partial reaction (PR)≥50% after neoadjuvant chemotherapy then receive definitive radiotherapy with concurrent cisplatin-based chemotherapy.

Group Type ACTIVE_COMPARATOR

Finolizumab

Intervention Type DRUG

200mg every 3 weeks (q3w) for 2 cycles.

Albumin-Bound Paclitaxel /nab-Paclitaxel

Intervention Type DRUG

260mg/m², day 1, every 3 weeks (q3w) for 2 cycles.

Cisplatin

Intervention Type DRUG

25mg/m², days 1-3, every 3 weeks (q3w) for 2 cycles.

Definitive radiotherapy

Intervention Type RADIATION

Definitive radiotherapy (68-70Gy) with concurrent cisplatin-based chemotherapy (25mg/m², days 1-3, every 3 weeks)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Finolizumab

200mg every 3 weeks (q3w) for 2 cycles.

Intervention Type DRUG

Albumin-Bound Paclitaxel /nab-Paclitaxel

260mg/m², day 1, every 3 weeks (q3w) for 2 cycles.

Intervention Type DRUG

Cisplatin

25mg/m², days 1-3, every 3 weeks (q3w) for 2 cycles.

Intervention Type DRUG

Definitive radiotherapy

Definitive radiotherapy (68-70Gy) with concurrent cisplatin-based chemotherapy (25mg/m², days 1-3, every 3 weeks)

Intervention Type RADIATION

Surgery with postoperative radiotherapy or chemoradiotherapy.

surgery with postoperative radiotherapy or chemoradiotherapy.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willingness to provide written informed consent;
2. Age ≥18 and ≤75 years;
3. Treatment-naïve for malignant disease;
4. Resectable stage III-IVA hypopharyngeal carcinoma with response of PR ≥ 50% after neoadjuvant therapy according to RECIST 1.1 ;
5. ECOG performance status 0-2.

Exclusion Criteria

1. Pregnancy or breastfeeding status;
2. Hypersensitivity to sintilimab, nab-paclitaxel, or their formulation components;
3. Poorly controlled cardiovascular conditions or other diseases;
4. Active or documented history of autoimmune diseases requiring systemic treatment;
5. Synchronous or metachronous malignancies;
6. Other conditions deemed ineligible for the study by investigators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ming Zhang

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ming Zhang, PhD

Role: PRINCIPAL_INVESTIGATOR

Eye & ENT Hospital, Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.